Suggested Remit: To appraise the clinical and cost effectiveness of nintedanib with pemetrexed and cisplatin followed by nintedanib monotherapy within its marketing authorisation for untreated unresectable malignant pleural mesothelioma.
Status In progress
Process STA 2018
ID number 1424

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
11 June 2018 - 09 July 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
24 April 2018 In progress, DHSC Referral Received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance